Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017240 | 1.00 | L3MBTL1 (0.38) | L3MBTL1F2PSMD10GPR119STAT3 | |
| SCHEMBL25937570 | 1.00 | L3MBTL1 (0.38) | L3MBTL1F2PSMD10GPR119STAT3 | |
| SCHEMBL30075379 | 1.00 | L3MBTL1 (0.38) | L3MBTL1F2PSMD10GPR119STAT3 | |
| SCHEMBL3868294 | 0.99 | F2 (0.39) | L3MBTL1F2PSMD10GPR119STAT3 | |
| SCHEMBL10641249 | 0.95 | F2 (0.39) | F2PSMD10GPR119STAT3CA12 | |
| SCHEMBL1649505 | 0.90 | F2 (0.40) | F2PSMD10STAT3CA12CA1 | |
| SCHEMBL25334266 | 0.86 | F2 (0.38) | F2PSMD10STAT3CA12CA1 | |
| SCHEMBL21458774 | 0.86 | F2 (0.38) | F2PSMD10STAT3CA12CA1 | |
| SCHEMBL21458406 | 0.86 | F2 (0.38) | F2PSMD10STAT3CA12CA1 | |
| SCHEMBL20548054 | 0.86 | F2 (0.38) | F2PSMD10STAT3CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | GENENTECHT, INC. (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4114830-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Genentech, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242506-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, TEAD2, TEAD4 | L3MBTL1 3597/4885F2 1060/4885PSMD10 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.